- Home
- SSTK vs GYRE Comparison
SSTK vs GYRE Comparison
Compare SSTK & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SSTK
- GYRE
- Stock Information
- Founded
- SSTK 2003
- GYRE 2002
- Country
- SSTK United States
- GYRE United States
- Employees
- SSTK N/A
- GYRE N/A
- Industry
- SSTK EDP Services
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- SSTK Technology
- GYRE Health Care
- Exchange
- SSTK Nasdaq
- GYRE Nasdaq
- Market Cap
- SSTK 644.4M
- GYRE 897.1M
- IPO Year
- SSTK 2012
- GYRE N/A
- Fundamental
- Price
- SSTK $19.91
- GYRE $7.80
- Analyst Decision
- SSTK Buy
- GYRE
- Analyst Count
- SSTK 4
- GYRE 0
- Target Price
- SSTK $43.67
- GYRE N/A
- AVG Volume (30 Days)
- SSTK 287.0K
- GYRE 222.6K
- Earning Date
- SSTK 08-05-2025
- GYRE 08-12-2025
- Dividend Yield
- SSTK 6.62%
- GYRE N/A
- EPS Growth
- SSTK N/A
- GYRE N/A
- EPS
- SSTK 1.09
- GYRE 0.02
- Revenue
- SSTK $963,567,000.00
- GYRE $100,643,000.00
- Revenue This Year
- SSTK $11.31
- GYRE $21.04
- Revenue Next Year
- SSTK $2.40
- GYRE $89.64
- P/E Ratio
- SSTK $18.37
- GYRE $95.83
- Revenue Growth
- SSTK 10.30
- GYRE N/A
- 52 Week Low
- SSTK $14.35
- GYRE $6.11
- 52 Week High
- SSTK $46.10
- GYRE $19.00
- Technical
- Relative Strength Index (RSI)
- SSTK 61.05
- GYRE 44.90
- Support Level
- SSTK $18.26
- GYRE $6.98
- Resistance Level
- SSTK $20.53
- GYRE $7.80
- Average True Range (ATR)
- SSTK 0.75
- GYRE 0.50
- MACD
- SSTK 0.15
- GYRE 0.00
- Stochastic Oscillator
- SSTK 79.33
- GYRE 51.90
About SSTK Shutterstock Inc.
Shutterstock Inc is a U.S.-based company that is engaged in the provision of digital content. The content segment, whose offerings include licenses for Images, Footage, Music, 3 Dimensional, and Generative AI content. Data, Distribution, and Service offerings address customer demand for products and services that are beyond its Content licenses. The company generates the majority of its revenue from Content offerings. Geographically the company generates the majority of its revenue from the Domestic market, but also has its presence in Europe and Rest of the Countries.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.